<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758393</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-GC-IgG4RD</org_study_id>
    <nct_id>NCT01758393</nct_id>
  </id_info>
  <brief_title>Glucocorticoids in Patients With IgG4-RD</brief_title>
  <official_title>A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-center clinical trial to compare the efficacy and
      safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related
      Disease. Patients will be followed for three months to measure the primary outcome and
      secondary outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>3 months</time_frame>
    <description>Complete Response(CR) is defined as resolution of clinical manifestations, biochemical tests (C-reactive Proteins and IgG or IgG4 levels), and imaging studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>3 months</time_frame>
    <description>Disease Response is measured by IgG4-RD Responder Index(IgG4-RD RI) and defined as:
Improvement of &gt; 2 points in the IgG4-RD RI over baseline
No disease flares, as assessed by the IgG4-RD RI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>3 months</time_frame>
    <description>Treatment-related adverse effect, including glucocorticoid-induced diabetes mellitus and infections.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>IgG4-related Disease</condition>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age 18-70 years old with informed consent

          -  Patients with IgG4-RD:

               1. swelling, sclerosing and inflammatory involvement of one or more organ, including
                  sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors,
                  retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis,
                  sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm,
                  lymphadenopathy, or other inflammatory conditions;

               2. elevated serum IgG4 (&gt;1.35 g/L)

               3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma
                  cell infiltration (and IgG4+ plasma cells on immunohistology when performed);

               4. exclusion of other diseases.

        Exclusion Criteria:

          -  Previously or currently received glucocorticoid and(or) immunomodulator

          -  Pregnancy or lactating

          -  Concurrent severe and/or uncontrolled and/or unstable diseases

          -  Patient with malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deptment of Rheumatology, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengchun Zhang</last_name>
    <role>Study Chair</role>
    <affiliation>Deptment of Rheumatology, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Chen, MD</last_name>
    <phone>+86-10-69158797</phone>
    <email>chenhua@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Zhang, MD</last_name>
      <phone>+86-10-69158795</phone>
      <email>zhangwen91@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Hua Chen, MD</last_name>
      <phone>+86-10-69158797</phone>
      <email>chenhua@pumch.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>December 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>December 24, 2012</last_update_submitted>
  <last_update_submitted_qc>December 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>IgG4-related disease</keyword>
  <keyword>IgG4-RD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 7, 2017</submitted>
    <returned>June 23, 2017</returned>
    <submitted>July 6, 2017</submitted>
    <returned>January 29, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

